Drs. Alicia Morgans and Jonathan Rosenberg share their insights into some interesting abstracts from the 2024 ASCO GU symposium: one covering a model to help predict response to neoadjuvant chemotherapy in patients with muscle invasive UC, and another regarding results from the PemCab study of pembrolizumab and cabozantinib in first‑line advanced UC.